Christof Seifarth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christof Seifarth has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Anna Lena Huber
Department of Ophthalmology, Medical University Innsbruck, Innsbruck, Austria
1 shared publication - Antonia Osl
Department of Ophthalmology and Optometry, Medical University Innsbruck, Anichstrasse, Innsbruck, Austria
1 shared publication - Claus Zehetner
Department of Ophthalmology and Optometry, Innsbruck Medical University, Anichstr. 35, Innsbruck, Austria
1 shared publication Georgios Blatsios
Department of Ophthalmology and Optometry, Medical University Innsbruck, Anichstrasse, Innsbruck, Austria
1 shared publication- Gertrud Haas
Department of Ophthalmology and Optometry, Medical University Innsbruck, Anichstrasse, Innsbruck, Austria
1 shared publication - Martina T. Kralinger
Department of Ophthalmology, Medical University Innsbruck, Innsbruck, Austria
1 shared publication
Latest Publications
- 1 April 2022
- Published by Medknow in Indian Journal of Ophthalmology - Case Reports
- Vol. 2 (2) , 497-499
Clinical and histological work-up of vitreoretinal metastases from cutaneous malignant melanoma
We report a rare case of vitreoretinal metastases from cutaneous malignant melanoma (CMM). A 76-year-old patient with CMM presented at our clinic complaining of floaters and blurred vision in his right eye. After conducting an exploratory vitrectomy, the diagnosis of vitreoretinal metastases from CMM was made. Histopathology of the enucleated eye demonstrated residual clusters of malignant cells in the vitreous and focal invasion of the inner retina. CMM metastatic to the retina and vitreous is very rare. A detailed ophthalmological examination in all patients with metastatic CMM and complaints of ocular symptoms is highly recommended.
- 1 April 2022
- Published by Medknow in Indian Journal of Ophthalmology - Case Reports
- Vol. 2 (2) , 497-499
Clinical and histological work-up of vitreoretinal metastases from cutaneous malignant melanoma
We report a rare case of vitreoretinal metastases from cutaneous malignant melanoma (CMM). A 76-year-old patient with CMM presented at our clinic complaining of floaters and blurred vision in his right eye. After conducting an exploratory vitrectomy, the diagnosis of vitreoretinal metastases from CMM was made. Histopathology of the enucleated eye demonstrated residual clusters of malignant cells in the vitreous and focal invasion of the inner retina. CMM metastatic to the retina and vitreous is very rare. A detailed ophthalmological examination in all patients with metastatic CMM and complaints of ocular symptoms is highly recommended.
- Open Access
- 1 January 2021
- Published by Wiley in Journal of Ophthalmology
- Vol. 2021 (1) , 7058505
Effects of Intravitreal Aflibercept on the Systemic Insulin‐like Growth Factor‐I and Vascular Endothelial Growth Factor‐A in Patients with Diabetic Retinopathy and Age‐Related Macular Degeneration
Purpose . To analyze the effect of intravitreal aflibercept injections on systemic levels of insulin‐like growth factor‐1 and vascular endothelial growth factor‐A in patients with diabetic retinopathy and age‐related macular degeneration. Methods . Vascular endothelial growth factor‐A and insulin‐like growth factor‐1 levels were determined before and one week and four weeks after intravitreal injection of aflibercept (2.0 mg/50 μ l) for 19 patients with age‐related macular degeneration (mean age, 76 ± 11 years) and 18 patients with diabetic retinopathy (mean age, 64 ± 14 years). Twenty‐two healthy individuals were enrolled as controls. Results . A significant decline in systemic vascular endothelial growth factor‐A level, from 43 (30–57) pg/ml at baseline to 8 (8–8) pg/ml ( p < 0.001) at week one and 17 (8–25) pg/ml ( p = 0.0054) at week four, was observed in the age‐related macular degeneration group. In the diabetic retinopathy group, vascular endothelial growth factor‐A levels declined from 53 (35–117) pg/ml to 2 (1–5) pg/ml ( p < 0.0001) one week after injection and 16 (13–22) pg/ml four weeks after injection ( p = 0.0327). At baseline, systemic insulin‐like growth factor‐1 concentration was higher in the diabetic retinopathy group (57 [37–99] pg/ml) than in the age‐related macular degeneration group (35 [24–51] pg/ml) ( p = 0.0056). A subgroup analysis showed that patients in the proliferative diabetic retinopathy subgroup had significantly higher systemic insulin‐like growth factor‐1 concentrations (71 [44.7–243] pg/ml) than those in the nonproliferative diabetic retinopathy subgroup (43 [29–66] pg/ml) ( p = 0.0048). Conclusions . The difference between the baseline systemic insulin‐like growth factor‐1 levels of the age‐related macular degeneration and diabetic retinopathy groups and the higher insulin‐like growth factor‐1 levels in the proliferative diabetic retinopathy subgroup one week after aflibercept therapy suggest that insulin‐like growth factor‐1 may play a role in the pathomechanism of diabetic retinopathy.
- 1 January 2021
- Published by Wiley in Journal of Ophthalmology
- Vol. 2021 (1) , 7058505
Open AccessEffects of Intravitreal Aflibercept on the Systemic Insulin‐like Growth Factor‐I and Vascular Endothelial Growth Factor‐A in Patients with Diabetic Retinopathy and Age‐Related Macular Degeneration
Purpose . To analyze the effect of intravitreal aflibercept injections on systemic levels of insulin‐like growth factor‐1 and vascular endothelial growth factor‐A in patients with diabetic retinopathy and age‐related macular degeneration. Methods . Vascular endothelial growth factor‐A and insulin‐like growth factor‐1 levels were determined before and one week and four weeks after intravitreal injection of aflibercept (2.0 mg/50 μ l) for 19 patients with age‐related macular degeneration (mean age, 76 ± 11 years) and 18 patients with diabetic retinopathy (mean age, 64 ± 14 years). Twenty‐two healthy individuals were enrolled as controls. Results . A significant decline in systemic vascular endothelial growth factor‐A level, from 43 (30–57) pg/ml at baseline to 8 (8–8) pg/ml ( p < 0.001) at week one and 17 (8–25) pg/ml ( p = 0.0054) at week four, was observed in the age‐related macular degeneration group. In the diabetic retinopathy group, vascular endothelial growth factor‐A levels declined from 53 (35–117) pg/ml to 2 (1–5) pg/ml ( p < 0.0001) one week after injection and 16 (13–22) pg/ml four weeks after injection ( p = 0.0327). At baseline, systemic insulin‐like growth factor‐1 concentration was higher in the diabetic retinopathy group (57 [37–99] pg/ml) than in the age‐related macular degeneration group (35 [24–51] pg/ml) ( p = 0.0056). A subgroup analysis showed that patients in the proliferative diabetic retinopathy subgroup had significantly higher systemic insulin‐like growth factor‐1 concentrations (71 [44.7–243] pg/ml) than those in the nonproliferative diabetic retinopathy subgroup (43 [29–66] pg/ml) ( p = 0.0048). Conclusions . The difference between the baseline systemic insulin‐like growth factor‐1 levels of the age‐related macular degeneration and diabetic retinopathy groups and the higher insulin‐like growth factor‐1 levels in the proliferative diabetic retinopathy subgroup one week after aflibercept therapy suggest that insulin‐like growth factor‐1 may play a role in the pathomechanism of diabetic retinopathy.